Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
#What Are The Current (2025) And Forecast (2029) Sizes Of The Pernicious Anemia Diagnosis And Treatment Market?
The market for diagnosing and treating pernicious anemia has seen robust growth over the past few years. This market is projected to expand from $1.42 billion in 2024 to $1.51 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.7%. Historically, this expansion has been driven by factors such as heightened awareness of vitamin B12 deficiency, a rising incidence of autoimmune disorders, an increase in the elderly population, enhanced physician training regarding anemia, and the accessibility of both oral and injectable vitamin B12 treatments.
The pernicious anemia diagnosis and treatment market is poised for robust expansion in the upcoming years. It is projected to reach $1.96 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.7%. This anticipated growth is primarily fueled by the increasing reach of telemedicine services, a heightened demand for prompt diagnosis, an intensified emphasis on personalized medicine, governmental initiatives for screening, and an escalating patient inclination towards non-invasive treatment options. Significant trends expected during this forecast period encompass the creation of extended-release vitamin B12 formulations, the expanding adoption of home-based diagnostic tools, the integration of artificial intelligence (AI) in detecting anemia, the proliferation of digital health monitoring devices, and continuous improvements in diagnostic technologies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24360&type=smp
What Are The Emerging Market Drivers Creating New Opportunities In The Pernicious Anemia Diagnosis And Treatment Industry?
The increasing occurrence of vitamin B12 deficiency is anticipated to fuel expansion in the pernicious anemia diagnosis and treatment market going forward. Vitamin B12 deficiency arises when the body has an insufficient amount of the vitamin to generate sufficient red blood cells, resulting in manifestations like fatigue, weakness, and neurological issues. The incidence of vitamin B12 deficiency is escalating because of the growing embrace of plant-based diets, which are frequently deficient in natural B12 sources and potentially causing insufficient intake if not adequately supplemented. Vitamin B12 deficiency facilitates the diagnosis and treatment of pernicious anemia, since diminished B12 levels directly hinder red blood cell production, prompting medical professionals to prescribe B12 supplementation as a fundamental and potent therapeutic approach. For instance, in February 2023, a report from the National Health Service (NHS), a UK-based government health organization, indicated that deficiencies in both vitamin B12 and folate are more common in older adults, impacting approximately 1 in 10 individuals 75 years of age or older and 1 in 20 of those 65 to 74 years of age. Consequently, the increasing incidence of vitamin B12 deficiency is propelling expansion in the pernicious anemia diagnosis and treatment market.
How Is The Pernicious Anemia Diagnosis And Treatment Market Classified Into Different Segments?
The pernicious anemia diagnosis and treatmentmarket covered in this report is segmented –
1) By Type: Complete Blood Count Test; Vitamin B12 Deficiency test; Intrinsic Factor Deficiency Test
2) By Treatment: Vitamin B12 Injections; Vitamin B12 Pills; Spray
3) By Route Of Administration: Injection; Oral; Intranasal
4) By End-User: Hospitals; Clinics; Diagnostic Centres; Other End-users
Subsegments:
1) By Complete Blood Count (CBC) Test: Red Blood Cell Count; Hemoglobin Concentration; Hematocrit Levels; Mean Corpuscular Volume (MCV); White Blood Cell Count; Platelet Count
2) By Vitamin B12 Deficiency Test: Serum Vitamin B12 Test; Methylmalonic Acid (MMA) Test; Homocysteine Test; Holotranscobalamin (Active B12) Test
3) By Intrinsic Factor Deficiency Test: Intrinsic Factor Antibody Test; Parietal Cell Antibody Test; Schilling Test; Gastrin Level Test
Which Competitive Trends Are Defining The Pernicious Anemia Diagnosis And Treatment Market Structure?
Leading companies in the pernicious anemia diagnosis and treatment market are prioritizing the creation of innovative remedies, such as vitamin B12 maintenance therapy solutions, to enhance patient adherence and long-term management of the condition. These vitamin B12 maintenance therapy solutions involve consistent, ongoing supplementation through various forms like oral tablets, injections, or nasal sprays, aiming to sustain adequate B12 levels and prevent the return of deficiency-related symptoms. For instance, in February 2024, Lupin Pharmaceuticals Inc., an India-based pharmaceutical company, introduced cyanocobalamin nasal spray, 500 mcg/spray, offering a non-invasive alternative for vitamin B12 supplementation. This nasal spray presents a convenient and effective method for patients with pernicious anemia who face difficulties with oral vitamin B12 forms. It works to improve B12 absorption and supports the management of vitamin B12 deficiency, ultimately leading to better patient compliance and treatment outcomes.
Which Industry Leaders Are Driving Innovation Across The Pernicious Anemia Diagnosis And Treatment Market?
Major companies operating in the pernicious anemia diagnosis and treatment market are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Lupin Limited, Eli Lilly and Company, Amgen Inc., DSM Nutritional Products AG, Bio-Rad Laboratories Inc., CSL Vifor Pharma, Daiichi Sankyo Co. Ltd., Par Pharmaceutical Companies Inc., AdvaCare Pharma, Monobind Inc.
Download The Full Report For Exclusive Market Findings:
How Do Regional Market Performances Compare Within The Pernicious Anemia Diagnosis And Treatment Industry?
North America was the largest region in the pernicious anemia diagnosis and treatment market in 2024. The regions covered in the pernicious anemia diagnosis and treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Pernicious Anemia Diagnosis And Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=24360&type=smp
Browse Through More Reports Similar to the Global Pernicious Anemia Diagnosis And Treatment Market 2025, By The Business Research Company
Anemia And Other Blood Disorder Drugs Global Market Report 2025
Chemotherapy Induced Anemia Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report
Hematology Drugs Global Market 2025
https://www.thebusinessresearchcompany.com/report/hematology-drugs-global-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model